This phase I trial will assess the safety and effectiveness of a new type of immunotherapy, known as CAR T-cell therapy, in patients with advanced renal cell carcinoma that has gotten worse or not responded to prior treatment.
This trial is treating patients with renal cell carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
CRISPR Therapeutics AG
This is a does escalation and expansion trial. Eligible patients will be sequentially assigned to receive CTX130 CD70-directed T-cell immunotherapy by IV-infusion following lymphodepleting chemotherapy.
Recruiting Hospitals Read More